MiSBIE: Mitochondrial Stress, Brain Imaging, and Epigenetics

Sponsor
Columbia University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04831424
Collaborator
Dartmouth College (Other), Centre National de la Recherche Scientifique, France (Other), Massachusetts General Hospital (Other), Technische Universit├Ąt Dresden (Other)
120
1
4
82.6
1.5

Study Details

Study Description

Brief Summary

The MiSBIE study collects biological, behavioral, psychosocial, neuropsychological, and brain imaging data in participants with either: normal mitochondrial function, individuals with the m.3243A>G mitochondrial DNA (mtDNA) mutation, and individuals a single large-scale mtDNA deletion. These defects induce mitochondrial allostatic load (MAL). The 2-day protocol, plus home-based data collection, will provide a comprehensive assessment of the multi-systemic dysregulation associated with MAL or mitochondrial dysfunction, and the link to physical and mental health-related symptoms.

Aim 1: Determine the influence of MAL on systemic AL biomarkers.

Aim 2: Establish the influence of MAL on stress reactivity profiles.

Aim 3. Examine the association between MAL and psychological functioning.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Trier social stress test
N/A

Detailed Description

Age-related physical and cognitive decline, as well as the risk of neurological diseases, are increased by the effects of psychosocial stress. Psychosocial stress triggers neuroendocrine, metabolic, cardiovascular, and inflammatory changes in the body. These changes vary in nature and magnitude between individuals, and are associated with long-term disease risk. However, the biological determinants of the stress response are not well understood.

This project aims to translate the preclinical findings (how mitochondria regulate the different organ systems and major stress response axes are activated during psychological stress) by studying a population of individuals with varying degree of mitochondrial dysfunction, and to test potential neural mechanism, and why some individuals respond more strongly than others to the same stressor.

Each participant will be studied over two consecutive days. Participants will be housed on campus to standardize study conditions. On Day 1, participants will donate blood and saliva, undergo a neuropsychological assessment, and complete questionnaires to assess psychosocial functioning and psychiatric symptoms. After lunch, the investigator will monitor dynamic changes in mental health-related biological outcomes (positive and negative affect, circulating levels of the inflammatory cytokine IL-6, and salivary cortisol) in response to a standardized laboratory challenge. On Day 2, participants will undergo a medical evaluation to assess clinical symptoms and undergo a whole brain neuroimaging session where both resting and stress elicited activity will be measured. A variant of the same stressor as on Day 1 will be used in the neuroimaging session. Participants will then be debriefed, concluding the individuals participation in the study. Participants also complete a home-based saliva and stool collection to examine diurnal variation in salivary hormones, and to examine microbiome composition. This translational project will generate a unique combination of complimentary molecular, cellular, and neuroimaging data that will advance our understanding of the links between mitochondria, the brain, and mental health-related outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
All participants will undergo TSST and have samples With DNA collected (blood plasma and serum, purified leukocytes, saliva, urine, buccal epithelial cells, hair are stored).All participants will undergo TSST and have samples With DNA collected (blood plasma and serum, purified leukocytes, saliva, urine, buccal epithelial cells, hair are stored).
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Mitochondrial Stress, Brain Imaging, and Epigenetics Study
Actual Study Start Date :
Jun 12, 2018
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Apr 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy controls

No diagnosis of mitochondrial disease

Behavioral: Trier social stress test
The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
Other Names:
  • TSST
  • Experimental: Mutation

    Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)

    Behavioral: Trier social stress test
    The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
    Other Names:
  • TSST
  • Experimental: Mutation with MELAS

    Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)

    Behavioral: Trier social stress test
    The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
    Other Names:
  • TSST
  • Experimental: Deletion

    Participants carrying a single, large-scale mtDNA deletion

    Behavioral: Trier social stress test
    The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
    Other Names:
  • TSST
  • Outcome Measures

    Primary Outcome Measures

    1. Average TSST-induced elevation in cortisol [Day 1 post challenge (approximately 2 hours)]

      This is designed to measure cortisol reactivity to the trier social stress test (TSST), quantified from salivary cortisol (LC-MS) over an 8-timepoints timecourse. The elevation will be measured as the area under the curve (AUC) for the cortisol time course.

    2. Average allostatic load index [Blood collected on Day 1]

      Groups will be compared on a quantitative allostatic load (AL) index integrating baseline fasting measures of neuroendocrine, immune and metabolic systems, urinary catecholamines, hematological measures, and hair/diurnal cortisol levels.

    Secondary Outcome Measures

    1. Average TSST-induced elevation in heart rate [Day 1 post challenge (approximately 2 hours)]

      Groups will be compared on heart rate (HR) as a measure of cardiovascular reactivity to stress, monitored using a continuous 3-lead ECG. The elevation will be computed from the baseline HR to the peak HR reached during the TSST.

    2. Correlation between anxiety and mitochondrial respiration [Day 1]

      The association between mitochondrial respiration using extracellular flux analysis (Seahorse) on blood lymphocytes, and anxiety symptoms measured using the state and trait anxiety inventory (STAI), will be quantified by a linear regression across all study participants.

    3. Average neuropsychological function [Day 2 neuropsychological session]

      Groups will be compared on the fluency/initiation domain of executive functioning assessed using the Delis-Kaplan Executive Function System (D-KEFS) test.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Men and women patients between 18 and 55 years of age

    • Willing to provide saliva samples and have venous catheter installed for blood collection during the hospital visit

    • Willing to provide informed consent and capacity to consent

    • Use of effective method of birth control for women of childbearing capacity

    • English Speaking

    Exclusion Criteria:
    • Individuals with cognitive deficit incapable of providing informed consent will not be included

    • Symptoms of flu or other seasonal infection four weeks preceding hospital visit

    • Raynaud's syndrome (Raynaud phenomenon)

    • Involvement in any therapeutic trials listed on clinicaltrials.gov, including exercise

    • Metal inside or outside the body or claustrophobia prohibitive to MRI testing

    • Diagnosed with mitochondrial disease m.3243A>G, or large scale mtDNA deletion (for healthy controls)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Columbia University Irving Medical Center New York New York United States 10032

    Sponsors and Collaborators

    • Columbia University
    • Dartmouth College
    • Centre National de la Recherche Scientifique, France
    • Massachusetts General Hospital
    • Technische Universit├Ąt Dresden

    Investigators

    • Principal Investigator: Martin Picard, PhD, Columbia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Martin Picard, Associate Professor of Behavioral Medicine (in Psychiatry and Neurology), Columbia University
    ClinicalTrials.gov Identifier:
    NCT04831424
    Other Study ID Numbers:
    • NYSPI 7424
    First Posted:
    Apr 5, 2021
    Last Update Posted:
    Jul 19, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Martin Picard, Associate Professor of Behavioral Medicine (in Psychiatry and Neurology), Columbia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2022